



\*Image for illustrative purposes only.

# Start an Impactful Conversation With Patients About HPV Vaccination

**GARDASIL<sup>®</sup>9 Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)**  
GARDASIL<sup>®</sup>9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases; premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types and genital warts (*Condyloma acuminata*) caused by specific HPV types.<sup>1</sup>

## WHY does prevention of HPV-related cancers and diseases matter?


Human papillomavirus (HPV) is a common sexually transmitted virus that may lead to infections associated with certain cancers and other diseases, including cervical, anal, vaginal, vulvar cancer, and genital warts.<sup>2</sup>



**About 8 in 10 sexually active men and women will be infected** with one or more sexually transmitted HPV types at some time in their lives.<sup>3</sup>

**Most HPV infections are spontaneously cleared on their own.**

However, persistent HPV infections with a high-risk HPV type can lead to HPV-related cancers and diseases.<sup>4</sup>



HPV-related cancers and diseases include **cervical, vulvar, and vaginal cancer** in women, and **anal cancer** and **genital warts** in both men and women.<sup>1,a</sup>




## Who is the HPV vaccine for?

- GARDASIL<sup>®</sup>9 is a vaccine for children and adolescents from 9 years of age and **adults**.<sup>5</sup>
- GARDASIL<sup>®</sup>9 has been studied in **males 9 to 26 years of age** and **females 9 to 45 years of age**.<sup>5</sup>

**A recommendation from a healthcare provider may affirm patients' perceptions of the value of vaccination<sup>6</sup>**

**The decision to receive the HPV vaccine is strongly governed by the decisions of policy makers, healthcare professionals, and parents.<sup>8</sup>**



\*Image for illustrative purposes only.

**Most HPV infections are spontaneously cleared on their own.** However, persistent HPV infections with a high-risk HPV type can lead to HPV-related cancers and diseases.<sup>4</sup>

# A.C.T. on a vaccination plan for patients

## 1 APPROACH

### PATIENTS WITH PURPOSE

When communicating messages about the HPV vaccine, remember to:

- Tailor your message to your target audience<sup>8</sup>
- Use clear and simple language (no jargon)<sup>8</sup>
- Include a call to action<sup>8</sup>

## 2 CONVERSE

### WITH PATIENTS ABOUT HPV VACCINATION

Keep these potential conversation starters on hand:

“ Have you received the HPV vaccine? If you haven't, we can talk more about that today. ”

“ You can consider getting the HPV vaccine as it may help protect you from cervical cancer and some other HPV-related cancers and diseases.<sup>1</sup> ”

## 3 TACKLE

### FREQUENTLY ASKED QUESTIONS

Have these answers ready for common queries from patients.



**Why should I get the HPV vaccine?**

HPV vaccination can help protect against certain HPV-related diseases. GARDASIL<sup>®</sup>9 is indicated for active immunisation against premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types, and genital warts (*Condyloma acuminata*) caused by specific HPV types.<sup>1,3</sup>



**Can I get GARDASIL<sup>®</sup>9 if I've already had HPV?**

Even if you've already had an HPV infection, you can still receive HPV vaccination. **If you're already infected with one type of HPV contained in the vaccine, GARDASIL<sup>®</sup>9 will help protect you against the other 8 types.** However, the vaccine cannot treat an existing HPV infection.<sup>1,10</sup>



**Can men benefit from HPV vaccination?**

Yes, as persistent HPV infection may lead to anal cancer and genital warts in men.<sup>9,a</sup>



**Which cancers does GARDASIL<sup>®</sup>9 help protect against?**

GARDASIL<sup>®</sup>9 may help protect against:

- Cervical cancer<sup>1</sup>
- Vulvar and vaginal cancers<sup>1</sup>
- Anal cancer<sup>1</sup>



**How much does GARDASIL<sup>®</sup>9 cost for adults over 25 y/o?**

Prices vary between different providers in the UK.

Note: The vaccine is for prophylactic use only and has no effect on active HPV infections or established clinical disease. The vaccine has not been shown to have a therapeutic effect.

**Most HPV infections are spontaneously cleared on their own.** However, persistent HPV infections with a high-risk HPV type can lead to HPV-related cancers and diseases.<sup>4</sup>

# RECOMMENDED SCHEDULE FOR GARDASIL®9<sup>1</sup>

Individuals 15 years of age and older at time of first injection:

15 & UP 

## 3-dose schedule:\*\*\*

1<sup>st</sup> dose 

AT  
ELECTED DATE

2<sup>nd</sup> dose 

THE SECOND DOSE  
SHOULD BE ADMINISTERED  
AT LEAST ONE MONTH  
AFTER THE FIRST DOSE

3<sup>rd</sup> dose 

THE THIRD DOSE SHOULD  
BE ADMINISTERED AT  
LEAST 3 MONTHS AFTER  
THE SECOND DOSE

\*\*\*All three doses should be given within a 1-year period.



Please refer to the local prescribing information or full Summary of Product Characteristics (SmPC) for complete dosing information.

<https://www.medicines.org.uk/emc/product/7330/pil>



Let your patients know that **the HPV vaccine is offered by the NHS to children aged 12-13 as well as girls under 25 and boys born after 1 September 2006 who missed having the vaccine at school.**

## GARDASIL®9 helps protect against 9 HPV types that may lead to approximately:



Most HPV infections are spontaneously cleared on their own. However, persistent HPV infections with a high-risk HPV type can lead to HPV-related cancers and diseases.<sup>4</sup>



**Most HPV infections are spontaneously cleared on their own.** However, persistent HPV infections with a high-risk HPV type can lead to HPV-related cancers and diseases.<sup>4</sup>

**Click to learn more about HPV vaccination.**

HPV = human papillomavirus

<https://www.msconnect.co.uk/products/gardasil-9/>

<sup>a</sup>Not all cervical, vulvar, vaginal, and anal cancers are caused by HPV.<sup>12</sup>

## Prescribing Information:

### **Gardasil® 9 Prescribing information for Great Britain**

### **Prescribing information for Northern Ireland**

If you require MSD Medical Information, please contact:  
medicalinformationuk@msd.com (enquiries from Great Britain) +44 (0) 208 154 8000  
medinfoni@msd.com (enquiries from Northern Ireland) +353 (0) 129 98700

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

## **Before prescribing or administering GARDASIL®9, please read the full prescribing information or full Summary of Product Characteristics (SmPC).**

### References

1. Gardasil® 9 Prescribing Information for GB. Summary of Product Characteristics. Available at: <https://www.emcpi.com/pi/32240> (accessed August 2024).
2. European Cancer Organisation. Viral Protection: Achieving the Possible. A Four Step Plan for Eliminating HPV Cancers in Europe. Published June 11, 2024. Accessed July 18, 2024. Available at: <https://www.european-cancer.org/resources/publications/reports/viral-protection-achieving-the-possible-a-four-step-plan-for-eliminating-hpv-cancers-in-europe.html>.
3. World Health Organization (WHO). Questions and Answers About Human Papillomavirus (HPV). Published January 2020. Accessed July 26, 2024. Available at: [https://cdn.who.int/media/docs/librariesprovider2/default-document-library/who-hpv-qa.pdf?sfvrsn=d0bf716b\\_3](https://cdn.who.int/media/docs/librariesprovider2/default-document-library/who-hpv-qa.pdf?sfvrsn=d0bf716b_3).
4. European Centre for Disease Prevention and Control. Guidance for the Introduction of HPV vaccines in EU countries. An update. Published September 2012. Accessed July 18, 2024. Available at: [https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/20120905\\_GUI\\_HPV\\_vaccine\\_update.pdf](https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf).
5. Gardasil® 9 . Summary of product characteristics. Available at : <https://www.medicines.org.uk/emc/product/7330/pil#about-medicine>. Accessed August 2024.
6. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing Vaccination: Putting Psychological Science Into Action. *Psychol Sci Public Interest*. 2017;18(3):149-207. doi:10.1177/1529100618760521.
7. Ferrer, H.B., Trotter, C., Hickman, M. et al. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. *BMC Public Health* 14, 700 (2014). Available at: <https://doi.org/10.1186/1471-2458-14-700>.
8. World Health Organization (WHO). HPV vaccine communication. Special considerations for a unique vaccine: 2016 update. Published 2017. Accessed July 30, 2024. Available at: <https://iris.who.int/bitstream/handle/10665/250279/WHO-IVB-16.02-eng.pdf?sequence=1>.
9. Meites E, Gee J, Unger E, Markowitz L. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 11: Human Papillomavirus. Updated August 2021. Accessed July 18, 2024. Available at: <https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-11-human-papillomavirus.html>.
10. Royal College of Physicians of Ireland. NIAC Immunisation Guidelines. Chapter 10. Human papillomavirus. Published June 6, 2023. Accessed July 30, 2024. Available at: [https://rcpi.access.preservica.com/uncategorized/IO\\_4a962f3d-d504-4c3c-aae9-968c04de60f5/](https://rcpi.access.preservica.com/uncategorized/IO_4a962f3d-d504-4c3c-aae9-968c04de60f5/).
11. Centers for Disease Control and Prevention (CDC). Sexually transmitted infections treatment guidelines, 2021 - human papillomavirus (HPV) infection. Last reviewed July 22, 2021. Accessed August 5, 2024. Available at: <https://www.cdc.gov/std/treatment-guidelines/hpv.htm>.